Trevi Therapeutics Q2 net loss widens on higher R&D costs - TRVI News | RalliesTrevi Therapeutics Q2 net loss widens on higher R&D costs
T
TRVI• Outlook
- Company expects to initiate Phase 3 OCEAN-2 trial in IPF-related chronic cough in Q3 2026
- Topline results from Phase 2b LAKE trial in RCC expected in H2 2027
- Company expects current cash to fund operations into 2030, excluding commercial launch costs
Overview
- US biopharmaceutical firm's Q2 net loss widened yr/yr amid higher R&D and G&A expenses
- Company ended Q2 with $318.9 mln in cash, boosted by April stock offering
- Cash runway expected to extend into 2030, supporting ongoing and planned clinical trials
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|
| Q2 Loss Per Share | | $0.11 | |
| Q2 Net Loss | | $17.80 mln | |
| Q2 Income from Operations | | -$20.51 mln | |
| Q2 Operating Expenses | | $20.51 mln | |
| Q2 Pretax Loss | | $17.82 mln | |
Result Drivers
- Clinical trial spending - Higher R&D expenses driven by increased clinical development costs for Phase 3 OCEAN-1, Phase 2b LAKE, Phase 3 OCEAN-2 trials and Phase 1 studies
